Navigation Links
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Date:6/5/2009

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated disease and cancer, today announced that Glenn Rice, President and COO will present on Wednesday, June 10, at 11:30 a.m. ET at the 8th Annual Needham Life Sciences Conference taking place at the New York Palace Hotel.

There will be a live webcast of the presentation, which will be accessible through a link posted on the home page and investor relations section of the PCYC website. The webcast will be available for replay through June 26, 2009.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

    Contact:
    Ramses Erdtmann
    VP Finance
    408-215-3325


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics Files Registration Statement for Rights Offering
2. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
4. Pharmacyclics Secures $5.0 Million in Debt Financing
5. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
7. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
8. Pharmacyclics Announces It Received Nasdaq Notification
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
11. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 On ... trading session at 5,817.69, down 0.07%; the Dow Jones ... and the S&P 500 closed at 2,345.96, marginally dropping ... sectors closed in green, 4 sectors finished in red, ... Friday, Stock-Callers.com has initiated reports coverage on the following ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):